Valuation: Sutro Biopharma, Inc.

Market Cap 391M 341M 315M 290M 547M 37.61B 559M 3.76B 1.48B 18.42B 1.47B 1.43B 63.41B P/E 2026 *
-2.76x
P/E 2027 * -3.21x
Enterprise Value 391M 341M 315M 290M 547M 37.61B 559M 3.76B 1.48B 18.42B 1.47B 1.43B 63.41B EV / Sales 2026 *
8.76x
EV / Sales 2027 * 12.4x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * -
1 day-0.67%
1 week-20.72%
Current month-29.01%
1 month-17.04%
3 months-25.29%
6 months+70.55%
Current year+103.72%
1 week 23.07
Extreme 23.07
29.88
1 month 23.07
Extreme 23.07
34.05
Current year 10.15
Extreme 10.15
43.85
1 year 7.15
Extreme 7.15
43.85
3 years 5.23
Extreme 5.231
61.3
5 years 5.23
Extreme 5.231
237
10 years 5.23
Extreme 5.231
283
Manager TitleAgeSince
Chief Executive Officer 55 13/03/2025
Director of Finance/CFO 53 02/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2026
Director TitleAgeSince
Director/Board Member 70 01/08/2009
Director/Board Member 67 01/02/2017
Director/Board Member 51 25/07/2018
Date Insider Type Main position Quantity % Market Cap.
6/5/26 A Free

Director

10,000 0.0603%
6/5/26 A Free

Director

10,000 0.0603%
6/5/26 A Free

Director

10,000 0.0603%
Change 5-day change 1-year change 3-year change Capi.($)
-0.67%-20.72%+207.74%-51.50% 391M
-7.17%-4.39%+45.51%+79.00% 52.1B
+0.24%-1.54%+53.22%+71.85% 53.83B
+0.80%-6.31%+3.98%+423.29% 23.48B
-0.09%-0.01%-17.62%-14.67% 23.13B
-5.95%-2.58%+30.67%-9.58% 19.36B
-1.14%+0.03%+31.57%-30.42% 17.56B
-5.16%-7.00%+168.44%+306.37% 15.2B
-6.91%-5.83%+26.53%+636.97% 14.83B
+0.43%-1.03%+24.63%+191.40% 14.06B
Average -2.56%-4.43%+57.47%+160.27% 23.39B
Weighted average by Cap. -2.80%-2.39%+40.40%+143.78%

Financials

2026 *2027 *
Net sales 44.56M 38.94M 35.94M 33.12M 62.43M 4.29B 63.82M 430M 169M 2.1B 167M 164M 7.24B 31.56M 27.58M 25.45M 23.46M 44.21M 3.04B 45.19M 304M 120M 1.49B 119M 116M 5.12B
Net income -137M -120M -111M -102M -192M -13.22B -197M -1.32B -521M -6.48B -516M -504M -22.29B -150M -131M -121M -112M -211M -14.49B -215M -1.45B -570M -7.09B -565M -552M -24.42B
Net Debt - -
Logo Sutro Biopharma, Inc.
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
Employees
133
Date Price Change Volume
17/07/26 $23.57 -0.67% 330,666
16/07/26 $23.73 -8.73% 297,538
15/07/26 $26.00 -0.12% 442,940
14/07/26 $26.03 -6.50% 219,597
13/07/26 $27.84 -6.36% 210,748
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
23.57USD
Average target price
47.75USD
Spread / Average Target
+102.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STRO Stock